Search

The commercial chemotherapeutant formulations SLICE® and AlphaMax® [active ingredients emamectin benzoate (EB) and deltamethrin respectively] are used in fin fish aquaculture to control parasitic sea lice. In some regions, the use of these substances has drawn concern from the commercial fishing industry regarding potential adverse effects on non-target organisms. In the present work, biodegradation of EB and deltamethrin, and their commercial formulations, was investigated over 135 days at 4 and 10°C in fresh marine sediments collected from underneath an active open net-pen salmon farm. EB incubated as either pure substance or commercial formulation was recalcitrant at both temperatures under abiotic and biotic conditions. Deltamethrin incubated alone or as its commercial formulation degraded slowly at 10°C (t1/2 = 330 ± 107 and 201 ± 27.1 days respectively). At 4°C, deltamethrin degradation was only significant following incubation as commercial formulation (t1/2 = 285 ±112 days). Degradation rates of EB and deltamethrin as pure substances versus their commercial formulations were not statistically different. Depletion of deltamethrin was observed in 10°C inactive sediments indicating that transformation occurred (at least in part) via an abiotic pathway. Overall, these data provide further insight into the fate and persistence of EB from the ongoing use of SLICE® in British Columbia's salmon aquaculture industry. AlphaMax® is not registered in Canada but is used in other salmon farming countries to control sea lice.

This study aimed to assess the role of specific human papillomavirus type 16 (HPV-16) variants, in combination with p53 codon 72 polymorphism genotypes, in cervical carcinogenesis. An initial sequence analysis of HPV-16 long control, E6 and E7 regions of 53 well-defined cervical samples containing HPV-16 revealed that a T to G transition at nucleotide position 350 within the E6 open reading frame was the most common variation, the frequency of which seemed to decrease with increasing severity of the lesion. Therefore, a total of 246 cervical samples of residents of The Netherlands was specifically analysed for HPV-16 350G/T variants and/or p53 codon 72 genotypes. These comprised HPV-negative normal cervical scrapes (n=40), normal cervical scrapes containing HPV-16 (n=46), scrapes containing HPV-16 from women with abnormal cervical cytology participating in a non-intervention follow-up study without (n=38) and with (n=51) a histologically proven cervical intraepithelial neoplasia (CIN) III lesion at the end of the study, and cervical squamous cell carcinomas (n=71). Neither specific HPV-16 350G/T variants nor specific p53 genotypes were associated with a higher risk of developing CIN III or cervical cancer. However, HPV-16 350T variants were significantly over-represented in p53 Arg homozygous women with cervical cancer. This suggests that, in p53 Arg/Arg women, infection with HPV-16 350T variants confers a higher risk of cervical cancer.